TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20028830

Group type: EXPERIMENTAL
Intervention: Partial Reinforcement (full dose 25% to 50% of the time, placebo other times)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dose Control (continuous reinforcement with 25% to 50% of the initial dose)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Therapy (active drug every treatment with 100% of the initial dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Partial Reinforcement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dose Control
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Therapy
Number of subjects: 46
Study: 18400458

Group type: EXPERIMENTAL
Intervention: Internal ports with topical anesthetic
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Peripheral access via venipuncture
Number of subjects: 55

Group type: COMPARATOR
Intervention: External line access
Number of subjects: 55
Study: 16258594

Group type: COMPARATOR
Intervention: Physiological saline 5 ml (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg + dexamethasone 8 mg (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg + droperidol 1.25 mg (Group C)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (Group D)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg (Group E)
Number of subjects: 150
Study: 12069361

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (average 6.4 +/- 0.7 METs), exercised three times per week for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 23
Study: 10400032

Group type: EXPERIMENTAL
Intervention: Hepatic vascular exclusion with preservation of the caval flow (HVEPC)
Number of subjects: 40
Study: 7781632

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (38.4 mg hyperbaric lignocaine 5%)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (10.8 mg hyperbaric bupivacaine 0.5%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia
Number of subjects: 108
Study: 2184186

Group type: EXPERIMENTAL
Intervention: Caregiver-focused health care, education about dementia and caregiving, assistance with problem solving, regularly scheduled in-home respite, and a self-help family caregiver support group.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional community nursing care
Number of subjects: 60
Study: 6998536

Group type: EXPERIMENTAL
Intervention: Carbohydrate infusion at 0.025 MJ (6 kcal) per kg body weight per 24 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbohydrate infusion at 0.105 MJ (25 kcal) per kg body weight per 24 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbohydrate infusion at 0.167 MJ (40 kcal) per kg body weight per 24 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: Surgical stress
Number of subjects: 18
Study: 31472687

Group type: EXPERIMENTAL
Intervention: dr. Bart app
Number of subjects: 483

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 483
Study: 29355292

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (1 ml Betamethasone)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Direct approach corticosteroid injection (1 ml Betamethasone)
Number of subjects: 39
Study: 28129555

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) or acceptance and commitment therapy (ACT) for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study: 26561615

Group type: EXPERIMENTAL
Intervention: Intraduodenal whey protein hydrolysate at 3 kcal/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraduodenal whey protein hydrolysate at 1.5 kcal/min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control (0 kcal/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 kcal/min protein load in lean individuals
Number of subjects: 12
Study: 23398459

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% ointment applied twice weekly
Number of subjects: 27

Group type: COMPARATOR
Intervention: Topical vitamin E applied once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cold cream applied once daily
Number of subjects: 27
Study: 21498063

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once-daily
Number of subjects: 90
Study: 19077853

Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (CBT)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Group social skills training
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 129
Study: 16551272

Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate bar and cocoa beverage daily (total flavanols, 444 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matching isocaloric placebos daily (total flavanols, 19.6 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12939717

Group type: EXPERIMENTAL
Intervention: Rituximab (given weekly as a single agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (thrice-weekly dosing schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab concurrent with fludarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab with appropriate premedication and a stepped up dosing schedule
Number of subjects: 0
Study: 10940817

Group type: EXPERIMENTAL
Intervention: Dithranol cream A (dissolved)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dithranol cream B (dispersed)
Number of subjects: 10
Study: 9221629

Group type: EXPERIMENTAL
Intervention: 5-FU plus folinic acid (5-FU/FA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU plus levamisole (5-FU/levamisole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional treatment (portal vein or intraperitoneal) combined with systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy (autologous tumor cell-BCG or monoclonal antibody treatment)
Number of subjects: 0
Study: 8458725

Group type: EXPERIMENTAL
Intervention: Biased condition emphasizing high prevalence of headaches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 60
Study: 3541501

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30776013

Group type: EXPERIMENTAL
Intervention: Unfamiliar/then familiar area assessment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Unfamiliar/unfamiliar assessment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Familiar/unfamiliar assessment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Navigational problems
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Drive Home Maze Test (DHMT)
Number of subjects: 43
Study: 29388288

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (40 mL of 0.25% bupivacaine)
Number of subjects: 90
Study: 28066103

Group type: EXPERIMENTAL
Intervention: Sertaconazole
Number of subjects: 179

Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 179
Study: 1441863

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus adrenaline 75 mg + 150 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus adrenaline 50 mg + 100 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus adrenaline 25 mg + 50 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative analgesics administration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surgeon's acceptance of the method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient preference for intra-articular analgesia
Number of subjects: 60
Study: 22055339

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 20417005

Group type: EXPERIMENTAL
Intervention: Narrative intervention along with an educational message about colorectal cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational message about colorectal cancer screening
Number of subjects: 0
Study: 21318060

Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at bedtime (21:00-24:00)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin glargine injection at breakfast (06:00-09:00)
Number of subjects: 28
Study: 15642765

Group type: EXPERIMENTAL
Intervention: 1-hour, one-on-one teaching session with a nurse educator
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard discharge process
Number of subjects: 223
Study: 12846628

Group type: EXPERIMENTAL
Intervention: Queen's Square bladder stimulator
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 43
Study: 10592547

Group type: EXPERIMENTAL
Intervention: Medication treatment (TM)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Diet treatment
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Fibrates, Statins, Resins
Number of subjects: 331

Group type: COMPARATOR
Intervention: Not treated with medication
Number of subjects: 331
Study: 8947980

Group type: EXPERIMENTAL
Intervention: Intranasal metoclopramide 20 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 2567792

Group type: EXPERIMENTAL
Intervention: Very low-dose aspirin plus dipyridamole
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard anticoagulant therapy
Number of subjects: 249
Study: 1226582

Group type: EXPERIMENTAL
Intervention: VK744 (300 mg TID for 2 days before, 5 days during, 3 days after saturation dive)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VK744
Number of subjects: 12
Study: 31564299

Group type: EXPERIMENTAL
Intervention: Targeting subclinical inflammation in rheumatoid arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategies
Number of subjects: 0
Study: 27496823

Group type: EXPERIMENTAL
Intervention: Waterproof cast
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nonwaterproof cast
Number of subjects: 26
Study: 25257824

Group type: EXPERIMENTAL
Intervention: In-office bleaching with a 2-day interval
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-office bleaching with a 7-day interval
Number of subjects: 40
Study: 23992999

Group type: EXPERIMENTAL
Intervention: ProNOVA XR polymer-free sirolimus eluting stent system
Number of subjects: 50
Study: 21512889

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation [1.5 g/d n‐3 LCPUFA]
Number of subjects: 122

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: High-fish intake (HFI) reference group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Maternal n‐3 LCPUFA intake during the intervention period
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infant erythrocyte DHA status at 4 months of age
Number of subjects: 122
Study: 18165586

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (T10-11 block)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lower body warming to 38 degrees C
Number of subjects: 9
Study: 23079140

Group type: EXPERIMENTAL
Intervention: Palatal implant (PI) supported anchorage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional dental anchorage (DA)
Number of subjects: 30
Study: 16246962

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 4127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4127

Group type: EXPERIMENTAL
Intervention: Higher serum phosphate levels
Number of subjects: 4127
Study: 12362799

Group type: EXPERIMENTAL
Intervention: Iron solution plus ascorbic acid added to domestic drinking water
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo added to domestic drinking water
Number of subjects: 88
Study: 9699191

Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT + PT
Number of subjects: 0
Study: 7979623

Group type: EXPERIMENTAL
Intervention: Amphotericin B in traditional incremental dose regimen (0.05, 0.10, 0.25, 0.50 and 1.0 mg/kg body weight on days 1, 2, 3, 4, and > 4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amphotericin B at a constant 1 mg/kg bodyweight per day from day 1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatment regimens (incremental and constant dose)
Number of subjects: 120
Study: 2471448

Group type: EXPERIMENTAL
Intervention: Oral iron treatment
Number of subjects: 907

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907
Study: 1192712

Group type: EXPERIMENTAL
Intervention: Frusemide 120 nmol (40 mg) administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frusemide 60 nmol (20 mg) administered intravenously
Number of subjects: 0
Study: 29448309

Group type: EXPERIMENTAL
Intervention: Capecitabine with bevacizumab (CAPBEV)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Capecitabine alone (CAP)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Vascular invasion
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Stroma-high
Number of subjects: 965
Study: 27005591

Group type: EXPERIMENTAL
Intervention: Open AAA repair
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: High-risk group (SGVI score)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Low-risk group (SGVI score)
Number of subjects: 327
Study: 24761394

Group type: EXPERIMENTAL
Intervention: Symbicort 80/4.5 mg/inhalation, two puffs twice daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Symbicort 160/4.5 mg/inhalation, two puffs twice daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pulmicort 180 mcg/inhalation, two puffs twice daily
Number of subjects: 76
Study: 23720894

Group type: EXPERIMENTAL
Intervention: Mw vaccine plus MDT
Number of subjects: 270

Group type: COMPARATOR
Intervention: MDT only
Number of subjects: 270
Study: 20335459

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the left hemisphere (LH) and cathodal tDCS applied to the right hemisphere (RH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RH anodal/LH cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: LH anodal/RH cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 0
Study: 18697469

Group type: EXPERIMENTAL
Intervention: 1-month depot (Zoladex 3.6 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3-month depot (Zoladex LA 10.8 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 28
Study: 16032972

Group type: COMPARATOR
Intervention: Meloxicam (LaborMed Pharma)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Commercially available preparation (reference)
Number of subjects: 24
Study: 12450596

Group type: EXPERIMENTAL
Intervention: Direct stenting (group A, n = 171)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Stenting after predilation (group B, n = 164)
Number of subjects: 335
Study: 10027501

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Multivitamins excluding A
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Vitamin A and multivitamins
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085
Study: 7565948

Group type: EXPERIMENTAL
Intervention: cisapride (10 mg three times a day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg three times a day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: omeprazole (20 mg per day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: ranitidine plus cisapride (10 mg three times a day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: omeprazole plus cisapride
Number of subjects: 175

Group type: COMPARATOR
Intervention: cisapride alone
Number of subjects: 175

Group type: COMPARATOR
Intervention: ranitidine alone
Number of subjects: 175

Group type: COMPARATOR
Intervention: ranitidine plus cisapride
Number of subjects: 175
Study: 2255970

Group type: EXPERIMENTAL
Intervention: Flavoured sachets sold through private outlets and unflavoured sachets distributed through primary care in Bukura Division (experimental cell)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unflavoured sachets distributed free of charge through primary health care facilities in Novakholo Division (control cell)
Number of subjects: 0
Study: 540455

Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg twice daily)
Number of subjects: 12
Study: 31135053

Group type: EXPERIMENTAL
Intervention: Real-feedback group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Yoked-feedback group (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Real-feedback group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Yoked-feedback group
Number of subjects: 60
Study: 28917231

Group type: EXPERIMENTAL
Intervention: Low fat, ready to eat cereal, replacing two meals/day for two weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard dietary guidelines for weight loss
Number of subjects: 101
Study: 25831670

Group type: COMPARATOR
Intervention: 5ml of 0.9% saline intrauterine (Group P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5ml of 2% lidocaine intrauterine (Group L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5ml of 2% lidocaine intrauterine + 50mg of rectal diclofenac sodium (Group LD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient and surgeon satisfaction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Complication rates
Number of subjects: 90
Study: 23885143

Group type: EXPERIMENTAL
Intervention: Active Dietary Intervention (ADI) - 175 mg milk thistle extract, 20 mg secoisolariciresinol, 750 mg oat fiber extract, administered twice a day for 60 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active Dietary Intervention (ADI)
Number of subjects: 60
Study: 21484280

Group type: EXPERIMENTAL
Intervention: Mass media HIV prevention messages
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Community-based STI treatment and counseling
Number of subjects: 1383

Group type: COMPARATOR
Intervention: No mass media program (control)
Number of subjects: 1383
Study: 19661116

Group type: EXPERIMENTAL
Intervention: Renal dysfunction (eGFR <60 mL/min/1.73 m²)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Worsening renal function (decrease of eGFR of at least 15 mL/min/1.73 m² within 1 year)
Number of subjects: 274
Study: 17227997

Group type: EXPERIMENTAL
Intervention: Vitamin C (750 mg/day), Vitamin E (600 mg/day), and Beta-carotene (18 mg/day)
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1980
Study: 12872340

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg monthly
Number of subjects: 851

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 851
Study: 10972174

Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin milk concentrate (BIC) 20 g daily for 4 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 86
Study: 8730344

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs), n = 14
Number of subjects: 26

Group type: COMPARATOR
Intervention: ACE inhibitors, n = 12
Number of subjects: 26
Study: 1413739

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 4054203

Group type: EXPERIMENTAL
Intervention: Nisoldipine, 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nifedipine, 20 mg retard
Number of subjects: 8
Study: 31728025

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy arm
Number of subjects: 439

Group type: COMPARATOR
Intervention: Dose-dense treatment arm
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: High AR mRNA levels
Number of subjects: 439
Study: 29381494

Group type: EXPERIMENTAL
Intervention: Co-use of marijuana and tobacco
Number of subjects: 52

Group type: COMPARATOR
Intervention: Only use of tobacco
Number of subjects: 52
Study: 26883529

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Teaching as Usual (TAU)
Number of subjects: 115
Study: 24878327

Group type: EXPERIMENTAL
Intervention: Modified surgical technique with acellular dermal matrix graft (ADMG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group with acellular dermal matrix graft (ADMG)
Number of subjects: 15
Study: 22498230

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 554

Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 554
Study: 20117675

Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NV) intervention
Number of subjects: 0
Study: 18626830

Group type: EXPERIMENTAL
Intervention: Early abciximab administration before transfer to the catheterisation laboratory (27 patients)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Late abciximab administration in the catheterisation laboratory just before pPCI (32 patients)
Number of subjects: 59
Study: 15886988

Group type: EXPERIMENTAL
Intervention: Rigid gold implants
Number of subjects: 96

Group type: COMPARATOR
Intervention: Flexible platinum chains
Number of subjects: 96
Study: 11933903

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (Opalescence Quick) for 30 minutes/week for three weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide power bleach (Opalescence Xtra) for 30 minutes/week for three weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group: stored in distilled water at 37 degrees C for three weeks
Number of subjects: 27
Study: 9806046

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine (vaccine 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 0